MANA Condemns Executive Order for International Pricing Index Model to Change Part B and Part D Reimbursements

Washington, DC, September 14, 2020 – MANA strongly condemns the Executive Order issued by President Trump yesterday, aimed at lowering amounts paid for Medicare and Medicaid prescription medications. The Executive Order on Lowering Drug Prices by Putting America First institutes a Most Favored Nations price control policy, building off the Administration’s 2018 “International Pricing Index Model” (IPI model) for Medicare Part B drugs. Research shows that the foreign reference pricing proposals, if finalized, would hamper access to needed treatments,¹ diminish the capacity of rural and community physicians to deliver care and drive up costs for patients,² and harm research and development of new medicines.³

“This election year stunt to impose foreign government price controls for Part B and Part D medications by Executive Order only serves to give false hope to the elderly and poor covered by Medicare and Medicaid,” said Amy Hinojosa, President and CEO of MANA, A National Latina Organization. She continues, “This plan is simply unable to provide real value or any savings to out-of-pocket costs for patients. While misguided in normal times, this type of policy change is simply dangerous in the face of the global COVID-19 pandemic.”

###